Mark R Stroud

This inventor holds 11 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: The Biomembrane Institute, Blaze Bioscience, Inc., Seikagaku Corporation. Active years: 1991-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark R Stroud. Retrieved from https://idiyas.com/inventor/mark-r-stroud

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 8)

% Patents Active = 90.9

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1

Average Co-Inventor Count = 4.8

ph-index = 4

Forward Citations = 66(Granted Patents)

Company Filing History:

7 out of 37

The Biomembrane Institute

patents

4 out of 8

Blaze Bioscience, Inc.

patents

2 out of 195

Seikagaku Corporation

patents

4. 1 out of 2,173

University of Washington

patents

where one patent can have more than one assignee

Years Active: 1991-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048750 - Tissue-homing peptide conjugates and methods of use thereof (2024-07-30),

2. 11866466 - Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof (2024-01-09),

3. 11559580 - Tissue-homing peptide conjugates and methods of use thereof (2023-01-24),

4. 11013814 - Cartilage-homing peptide conjugates and methods of use thereof (2021-05-25),

5. 6294523 - Extended type 1 chain glycosphingolipids as tumor-associated antigens (2001-09-25),

6. 6133239 - Carbohydrate ligands (myelorollin) that cause E-selectin dependent cell (2000-10-17),

7. 6130205 - Method for determining susceptibility to Escherichia coli urinary tract (2000-10-10),

8. 6083929 - Extended type 1 chain glycosphingolipids as tumor-associated antigens (2000-07-04),

9. 5876715 - Antibodies that bind novel carbohydrate ligands (myelorollins) that (1999-03-02),

10. 5421733 - Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3 (1995-06-06),

11. 5030723 - Long-chain glycolipid structure (1991-07-09),

Title: The Innovative Contributions of Mark R. Stroud

Introduction

Mark R. Stroud is a prominent inventor based in Seattle, WA, known for his significant contributions to the field of biotechnology. With a total of 11 patents to his name, Stroud has made remarkable advancements in peptide technology, particularly in applications related to targeted drug delivery and immuno-oncology.

Latest Patents

Stroud's latest patents include groundbreaking work on tissue-homing peptide conjugates and methods of use thereof. These patents disclose peptides that can home, target, and bind to specific tissues such as cartilage or kidney, allowing for targeted delivery of active agents. Another notable patent focuses on tumor homing and cell-penetrating peptide-immuno-oncology agent complexes. These complexes are designed to penetrate the tumor microenvironment and deliver immuno-oncology agents effectively, even crossing the blood-brain barrier.

Career Highlights

Throughout his career, Mark R. Stroud has worked with notable organizations, including the Biomembrane Institute and Blaze Bioscience, Inc. His work has been instrumental in advancing the understanding and application of peptide technology in medical treatments.

Collaborations

Stroud has collaborated with esteemed colleagues such as Sen-itiroh Hakomori and Dennis M. Miller, contributing to the innovative research and development in his field.

Conclusion

Mark R. Stroud's contributions to biotechnology and peptide technology have paved the way for new therapeutic approaches in medicine. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.